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Vitamin D deficiency and prognostics among
patients with pancreatic adenocarcinoma
May Cho1, Parvin F Peddi2,5, Kevin Ding3, Ling Chen4, Denise Thomas1,2, Jian Wang6, Albert C Lockhart1,2,
Benjamin Tan1,2† and Andrea Wang-Gillam1,2*†
Abstract
Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported.
Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of
vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known
about the correlation between vitamin D status and prognosis in these patients.
Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma
who were treated at Siteman Cancer Center. Patients’ demographic information, clinical staging at the time of
vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a
serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25
(OH)D level of between 20 ng/mL and 30 ng/mL.
Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin
D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency,
and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite
patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be
associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.
Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic
adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic
adenocarcinoma, and its effects should be further examined in a prospective study.
Keywords: Vitamin D, Vitamin D receptor, Pancreatic cancer, Prognostic factors
Introduction
Pancreatic cancer is the fourth leading cause of cancer-
related death in the United States. In 2013, an estimated
45,220 new cases of pancreatic adenocarcinoma were di-
agnosed, and nearly 38,460 people died as a result of the
disease [1]. Surgery is the only curative measure, but
more than half of patients are not candidates for surgical
resection at the time of diagnosis, and the 5-year sur-
vival rate is just 6% [1].
Vitamin D is a steroid hormone that plays an essential
role in the maintenance of calcium, phosphate, and bone
metabolism. Emerging evidence demonstrates that vitamin
D has a plethora of antitumor properties as well, including
the induction of cell differentiation, the stimulation of
apoptosis, and the inhibition of cell proliferation, angio-
genesis, and metastasis [2,3]. Ample epidemiologic studies
have suggested that individuals with sufficient vitamin D
levels are at lower risk for multiple types of cancers, in-
cluding colorectal, breast, prostate, lung, and ovarian can-
cers [4]. For example, the risk of developing colorectal
cancer was 50% lower among individuals with serum 25-
hydroxyvitamin D (25[OH]D) levels of 33 ng/mL or more
as compared with those with 25(OH)D levels of 12 ng/mL
or less [5]. The risk of pancreatic cancer in association
with vitamin D levels has been controversial; one study
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suggested an increased risk of cancer with 25(OH)D levels
of more than 100 nmol/L [6], whereas another reported
that the plasma level of 25(OH)D was inversely associated
with the odds of developing pancreatic cancer [7]. A re-
cent Canadian study suggested that the genes involved in
the vitamin D pathway are associated with pancreatic can-
cer risk [8].
Vitamin D levels have also been shown to have an im-
pact on the clinical outcomes of several cancer types, in-
cluding breast, colon, lung, and prostate cancers as well as
leukemia and lymphoma [9-13]. For example, higher 25
(OH)D levels at the time of diagnosis in patients with
colorectal cancer were associated with a significant reduc-
tion in overall mortality (p = 0.02) and an improvement in
overall survival [10]. Patients with prostate cancer whose
serum 25(OH)D levels were medium (50–80 nmol/L) or
high (>80 nmol/L) had significantly better prognoses as
compared with those with low (<50 nmol/L) serum con-
centrations [11]. Although studies have suggested that
higher vitamin D levels are significantly associated with
improved survival among patients with certain cancers, to
date no study has examined the relationship of vitamin D
with pancreatic cancer survival.
We hypothesized that there is a high incidence of vitamin
D deficiency in the pancreatic cancer patient population,
because these patients frequently have exocrine dysfunc-
tion. Furthermore, we hypothesized that low vitamin D
levels may be associated with worse prognoses in this pa-
tient population as has been seen with other malignancies.
In this article, we report our study of the prevalence of vita-
min D deficiency among patients with pancreatic adenocar-
cinoma, and we evaluate the prognostic significance of
vitamin D levels for this patient population.
Materials and methods
We conducted a retrospective review of patients with pan-
creatic adenocarcinoma who were evaluated at Siteman
Cancer Center (SCC) in St. Louis, Missouri, between
December 2007 and June 2011. The retrospective registry
was established to capture all patients after institutional
review board approval was obtained. Patients with pancre-
atic adenocarcinoma who had at least one vitamin D level
recorded at the time of diagnosis or the first time that they
presented to the center were included in the study.
Patients were only excluded if they did not have their vita-
min D levels checked at their first presentation. Patients
with stage I and II pancreatic cancer usually presented to
the medical oncologists after surgery. Therefore, their first
recorded vitamin D levels were after their surgeries and
before their first chemotherapy treatments. The same
chemiluminescent assays were used to measure patient
vitamin D levels at this center throughout the study.
Patients’ demographic information, clinical stage at the
time of vitamin D assessment, vitamin D levels, and
clinical outcomes were collected directly from the institu-
tional electronic medical record system. Vitamin D levels
at the initial clinical visit and at later visits after supple-
mentation were recorded. Chemotherapy treatments were
given at the discretion of oncologists. Data regarding the
treatments that patients received were not collected.
Patients’ times of death were obtained from the electronic
medical record and verified by the Social Security Death
Index. In accordance with previous studies, vitamin D de-
ficiency was defined as a serum 25(OH)D level of less than
20 ng/mL; vitamin D insufficiency was defined as a 25
(OH)D level of 20 ng/mL to 30 ng/mL; and vitamin D
sufficiency was defined as a 25(OH)D level of at least
30 ng/mL [3,14]. Patients’ vitamin D levels at the time of
initial visit to SCC were used for prognostic studies.
Comparisons of patients’ mean vitamin D levels with re-
spect to baseline characteristics were carried out with the
use of the Student’s t-test. Demographic and clinical char-
acteristics among the three groups with regard to vitamin
D status (i.e., deficient, insufficient, or sufficient) were
compared via the chi-square test. Overall survival was de-
fined as the time from pathological diagnosis to the time of
death from any cause by June 2011. Survivors were cen-
sored at the date of last contact. The time to death in each
vitamin D group (i.e., a 25[OH]D level of ≥20 ng/mL
or <20 ng/mL) was described by the Kaplan-Meier product
limit method, and the between-group differences were
compared with the use of the log-rank test. Univariate and
multivariate analyses were performed for patients with
stage III and IV pancreatic cancer with the use of the Cox
proportional hazards model. All analyses were conducted
with a two-sided test at a significance level of 0.05. Statis-
tical analyses were performed with SAS 9.2 software (SAS
Institute, Cary, North Carolina).
Results
Patient characteristics
Of the 178 patients included in this study, 161 (90%) were
50 years old or older. The majority of the patients (87%)
were Caucasian. The sample population was nearly equally
divided between genders, with 82 (46%) being female and
96 (54%) being male. Most patients (64%) had advanced
disease (i.e., stage III and IV). The majority of patients in
this study had body mass indices of more than 25 kg/m2.
Vitamin D levels
Vitamin D status was analyzed across several variables: age,
race, gender, tumor stage, season in which vitamin D was
drawn, and BMI (Table 1). There were no statistically sig-
nificant differences in mean 25(OH)D levels between
groups with regard to age, gender, season, or BMI. Lower
mean 25(OH)D levels were seen in non-white patients as
compared with white patients (13.95 vs. 23 ng/mL; p =
0.0007). Interestingly, patients with stage I and II disease
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appeared to have lower 25(OH)D levels than patients with
advanced stage III and IV disease (19.33 vs. 23.71 ng/mL;
p = 0.0149). There was a trend toward higher vitamin D
levels during summer and autumn; however, the difference
was not statistically significant.
Of the 178 patients in the study, 87 (49%) had vitamin
D deficiency, and 44 (25%) had vitamin D insufficiency
(Table 2). Only 47 (26%) of the patients had sufficient
vitamin D levels. Vitamin D sufficiency was much lower
among non-white patients (12%) than white patients
(29%). Only 13 patients (20%) with stage I and II pancre-
atic adenocarcinoma had sufficient vitamin D levels,
whereas 34 patients (30%) with stage III and IV disease
had sufficient levels of vitamin D.
A subset of 71 patients with vitamin D deficiency or
insufficiency was supplemented with 50,000 units of
vitamin D weekly for 10 to 12 weeks. Vitamin D levels
were reassessed after supplementation. Forty-two of
these patients (55%) had not achieved sufficient vitamin
D levels at the time of reassessment, despite supplemen-
tation. The mean vitamin D level was 22 ng/mL even
after the course of vitamin D supplementation.
Prognostic significance
Figure 1 shows the overall correlation between the sur-
vival of patients with pancreatic cancer and their vitamin
D levels at the time of initial visit to SCC. Of 178 pa-
tients enrolled in this study, 82 died, and 96 were cen-
sored. The median overall length of survival was
447 days. For patients with all stages combined or stage
I and II diease, 25(OH)D levels of less than 20 ng/mL
did not affect overall survival. Vitamin D levels of less
than 20 ng/mL appeared to be associated with a worse
prognosis among patients with stage III and IV disease
(p = 0.0019). The multivariate analysis of patients with
stage III and IV disease showed that lower vitamin D
levels and lower BMIs had prognostic significance shown
in Table 3.
Discussion
Epidemiological studies have suggested a correlation be-
tween vitamin D status and an individual’s risk for pan-
creatic cancer [7]. There is a high prevalence of vitamin
D deficiency in the general population (41.6%) [15] and
among patients with other malignancies [16]. In our
single-institution study, the prevalence of vitamin D de-
ficiency and insufficiency was higher than that observed
in the general population and occurred in 74% of the
Table 1 Patient characteristics
Vitamin D level (ng/mL)
Patients No. (%) Mean Standard deviation P value
Age:
<50 years 17 (10) 20.59 8.70
≥50 years 161 (90) 22.30 12.98 0.4731
Race:
White 155 (87) 23.00 12.44
Non-white 23 (13) 13.95 10.89 0.0007
Gender:
Female 82 (46) 22.17 12.83
Male 96 (54) 22.10 12.52 0.9722
Tumor stage:
I and II 64 (36) 19.33 9.85
III and IV 114 (64) 23.71 13.74 0.0149
Season:
Autumn 28 (16) 23.57 13.80
Winter 56 (31) 21.18 11.80
Spring 60 (34) 21.12 12.61
Summer 34 (19) 24.32 13.17 0.5566
Body mass index:
<25 kg/m2 68 (38) 22.06 11.43
≥25 kg/m2 110 (62) 22.18 13.37 0.1659
Table 2 Distribution of vitamin D status
Deficient
vitamin D
Insufficient
vitamin D
Sufficient
vitamin D P
value(<20 ng/mL) (20–29 ng/mL) (≥30 ng/mL)
No. (%) No. (%) No. (%)
All patients 87 (49) 44 (25) 47 (26)
Age:
<50 years 6 (35) 9 (53) 2 (12)
≥50 years 81 (50) 35 (22) 45 (28) 0.29
Race:
White 70 (45) 40 (26) 45 (29)
Non-white 17 (74) 4 (17) 2 (9) 0.029
Gender:
Female 38 (46) 22 (27) 22 (27) 0.79
Male 49 (51) 22 (23) 25 (26)
Tumor stage:
I and II 36 (56) 15 (23) 13 (20)
III and IV 51 (45) 29 (25) 34 (30) 0.27
Season:
Autumn 11 (40) 9 (32) 8 (28)
Winter 31 (55) 10 (18) 15 (27)
Spring 33 (55) 14 (23) 13 (22)
Summer 12 (35) 11 (32) 11 (32) 0.39
Body mass
index:
<25 kg/m2 30 (44) 19 (28) 19 (28)
≥25 kg/m2 57 (52) 25 (23) 28 (25) 0.058
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178 patients studied. Klapdor and colleagues reported an
even higher rate of 92.4% of 103 patients with pancreatic
cancer who had 25(OH)D levels of less than 30 ng/mL
[17]. More than 90% of our non-white pancreatic cancer
patients had vitamin D deficiencies; this was consistent
with the findings of other studies that also reported a high
prevalence of vitamin D deficiency among non-whites.
To our knowledge, none of the prior studies assessed
the correlation between pancreatic cancer stage and vita-
min D status. Surprisingly, our study demonstrated that
patients with stage I and II disease had lower vitamin D
levels than patients with stage III and IV disease. Most
of the patients with stage I and II disease were referred
to medical oncologists after their surgeries; thus, their
vitamin D levels were first checked after their opera-
tions. Among patients undergoing pancreatectomy, vita-
min D levels are thought to be lower as a result of the
surgical procedure itself in addition to associated exo-
crine dysfunction [18]. This idea is in alignment with the
reported high rate of vitamin D deficiency found among
patients after resection. The season in which the vitamin
D level was obtained did not have a statistical impact, al-
though higher levels were observed during summer and
autumn. Although some studies have stated that patients
with higher BMIs have lower vitamin D levels [19,20],
this was not observed in the current study. Patients with
pancreatic cancer have lower vitamin D levels, regardless
of the season or their BMI. Malabsorption and disease
burden have more of an impact on vitamin D levels in
these patients than synthetic insufficiency from the sun-
light or storage capacities.
Our study further evaluated the association between
baseline vitamin D levels and the prognoses of patients
with pancreatic cancer. The association of the vitamin D
level with the prognoses of various cancer populations
has been variable in the literature. Although a sufficient
vitamin D level was associated with a better prognosis in
patients with colon cancer [10,21] and a lower disease
relapse and death rate in patients with melanoma [22],
the prognostic value of the vitamin D level was not sta-
tistically significant in patients with non–small-cell lung
cancer [23], and it was controversial in patients with
breast cancer [24,25]. We did not find an association be-
tween vitamin D deficiency and pancreatic cancer prog-
nosis when all stages were combined. However, to our
knowledge, this study is the first to suggest a signifi-
cantly worse overall survival rate for patients with vita-
min D levels of less than 20 ng/mL with stage III or IV
Figure 1 Overall survival Kaplan-Meier plot for patients with
25-hydroxyvitamin D levels of less than 20 ng/mL and more
than 20 ng/mL with all stages of pancreatic cancer (A), with
stage I or II pancreatic cancer (B), and with stage III or IV
pancreatic cancer (C).
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pancreatic cancer. Multivariate analysis also confirms
that the vitamin D level has an impact on the prognosis
of pancreatic cancer. Although patients with stage I and
II pancreatic cancer have lower vitamin D levels than those
with stage III and IV, there is no significant association with
poorer outcomes. The prognostic significance of vitamin D
levels in patients with stage III and IV pancreatic cancer
should be further examined in a prospective study.
The expression of the vitamin D receptor (VDR) and its
polymorphisms modulate the activity of vitamin D, which
may in turn affect the prognosis of patients with pancre-
atic cancer. Certain VDR polymorphisms show prognostic
significance for melanoma, squamous cell cancer of the
head and neck, and non–small-cell lung cancer [23,26]. In
a recent genome-wide association study of the overall sur-
vival of patients with pancreatic cancer, VDR gene poly-
morphism was associated with several prognostic factors
[27]. Because patients with pancreatic cancer have a high
prevalence of vitamin D deficiency in general, patients
with lower VDR expression would have poorer prognoses
as well as poorer responses to chemotherapy as a result of
their vitamin D deficiencies. Our study was retrospective
in nature and, unfortunately, patient VDR levels are not
routinely checked, so we could not include VDR levels in
our analysis. However, the future prospective examination
of VDR levels in patients with pancreatic cancer is defin-
itely warranted.
Our study suggested that the routine vitamin D supple-
mentation of 50,000 International Units weekly for a short
period of time (i.e., 10–12 weeks) may not be adequate to
normalize vitamin D levels in most patients with pancre-
atic cancer. More prolonged supplementation may be re-
quired to achieve adequate levels. Exocrine pancreatic
insufficiency may add another layer of complexity, thereby
limiting sufficient supplementation with standard dosing.
One study used a higher dose of vitamin D supplementa-
tion of up to 20,000 International Units daily for individ-
uals with severe pancreatic exocrine insufficiency [17] and
reported the normalization of vitamin D levels by indi-
vidually adjusting oral vitamin D intake. The exact dose of
supplementation may vary with the degree of insufficiency
and the potential correction of the insufficiency with pan-
creatic enzymes. Regardless, the clinical impact of the
normalization of vitamin D levels on disease progression
and patient survival is still unknown and will require fu-
ture prospective trials.
The current study is limited by its retrospective nature,
the lack of accurate documentation of vitamin D supple-
mentation before the diagnosis of pancreatic cancer, and
the lack of control over vitamin D supplementation
Table 3 Univariate and multivariate cox regression analyses of different prognostic variables for overall survival in
patients with stage III and IV of pancreatic cancer
Univariate analysis Multivariate analysis
No. of patients P Value Regression coefficients (Standard error) Hazard ratio (95% confidence interval) P value
Age:
≥50 years 103 0.7990 0.109 (0.428) 1.101 (0.450-2.693) 0.8334
<50 years 11
Race:
Non-white 17 0.7842 0.095 (0.345) 1.020 (0.504-2.064) 0.9556
White 97
Gender: 0.2731
Female 52 0.1755 −0.334 (0.246) 0.751 (0.450-1.253)
Male 62
Vitamin D level:
<20 ng/mL 53 0.0024 0.752 (0.248) 1.991 (1.156 - 3.430) 0.0131
≥20 ng/mL 61
Season:
Autumn 19 0.5497 −0.436 (0.375) 0.648 (0.293-1.433) 0.1789
Spring 38 0.017 (0.303) 0.997 (0.549-1.812)
Summer 22 0.142 (0.335) 1.672 (0.808-3.459)
Winter 35
Body mass index:
≥25 kg/m2 72 0.0040 0.142 (0.335) 0.441 (0.265-0.733) 0.0016
<25 kg/m2 42
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regimens. This was a single-institution study, so our co-
hort may differ from other pancreatic cancer populations.
The study also demonstrates selection bias in that sicker
patients were probably referred to our tertiary cancer cen-
ter. The study attempted to not further limit the pool of
patients by allowing all patients with baseline vitamin D
level measurements to be included. Systemic treatment of
patients was not controlled in this study but that would
not be expected to bias the results in a particular way.
In summary, the current report confirms the high
prevalence of vitamin D deficiency and insufficiency
among patients with pancreatic cancer. Patients with
early-stage pancreatic cancer have lower vitamin D
levels as compared with those patients with advanced
disease. However, only in patients with stage III and
IV pancreatic cancer was there a significant association
with poorer outcomes. We recommend the systematic
screening of patients with pancreatic cancer for vitamin
D deficiency and the rigorous monitoring of these pa-
tients while they are receiving oral supplementation.
Further prospective investigations should be conducted
to study vitamin D supplementation for patients with
pancreatic cancer and to determine the prognostic value
of vitamin D levels and VDR expression in this patient
population.
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